Wedbush Comments on Xencor’s Q2 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Wedbush lowered their Q2 2025 earnings per share (EPS) estimates for Xencor in a research report issued to clients and investors on Wednesday, May 7th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($0.78) per share for the quarter, down from their prior estimate of ($0.60). Wedbush has a “Outperform” rating and a $31.00 price objective on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor’s Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.03) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.80) EPS, FY2026 earnings at ($3.20) EPS, FY2027 earnings at ($3.39) EPS, FY2028 earnings at ($4.29) EPS and FY2029 earnings at ($5.95) EPS.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $23.44 million. During the same quarter in the prior year, the company posted ($1.11) EPS. The business’s revenue for the quarter was up 104.6% compared to the same quarter last year.

A number of other equities analysts have also recently commented on XNCR. Wells Fargo & Company reduced their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. William Blair started coverage on Xencor in a report on Monday, April 21st. They issued an “outperform” rating for the company. Barclays cut their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research note on Thursday. Finally, StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Xencor Price Performance

Shares of Xencor stock opened at $8.33 on Monday. The business has a 50 day simple moving average of $10.73 and a two-hundred day simple moving average of $17.61. Xencor has a 12 month low of $7.16 and a 12 month high of $27.24. The stock has a market capitalization of $592.70 million, a P/E ratio of -2.60 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Insider Buying and Selling

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the sale, the executive vice president now owns 49,169 shares in the company, valued at approximately $542,334.07. This represents a 8.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.76% of the company’s stock.

Institutional Investors Weigh In On Xencor

A number of large investors have recently bought and sold shares of XNCR. RTW Investments LP grew its holdings in Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock valued at $55,218,000 after buying an additional 1,827,883 shares during the last quarter. BVF Inc. IL grew its holdings in Xencor by 169.3% during the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock valued at $52,596,000 after buying an additional 1,438,760 shares during the last quarter. Primecap Management Co. CA grew its holdings in Xencor by 8.6% during the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock valued at $103,857,000 after buying an additional 776,580 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in Xencor by 452.4% during the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock valued at $19,236,000 after buying an additional 685,557 shares during the last quarter. Finally, Finepoint Capital LP acquired a new stake in Xencor during the 4th quarter valued at $15,167,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.